DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b ) CONCLUSION.— The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the appl icant regards as his invention. Claim 5 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 5 contains the trademark/trade name “ UVX-8204 ” manufactured by Denka Company Limited . Where a trademark or trade name is used in a claim as a limitation to identify or describe a particular material or product, the claim does not comply with the requirements of 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), second paragraph. See Ex parte Simpson , 218 USPQ 1020 (Bd. App. 1982). The claim scope is uncertain since the trademark or trade name cannot be used properly to identify any particular material or product. A trademark or trade name is used to identify a source of goods, and not the goods themselves. Thus, a trademark or trade name does not identify or describe the goods associated with the trademark or trade name. In the present case, the trademark/trade name is used to identify/describe UV curable adhesive and, accordingly, the identification/description is indefinite. Allowable Subject Matter Claims 1-4 and 6-9 are allowed. Claim 5 would be allowable if rewritten or amended to overcome the rejection(s) under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA), 2nd paragraph, set forth in this Office action. The following is an examiner’s statement of reasons for allowance; and reasons for the indication of allowable subject matter: The closest prior art of record is Hosokawa (US 20170023596 equivalent to WO2015/156322 ). Hosokawa discloses (Fig 1B and 1C; and [0010]) a microchip for blood characterization testing comprising: a first and second flow channels (grooves) for flowing blood samples. The first flow channel has a first reaction part in which collagen and tissue thromboplastin are applied, and the second flow channel is coated with collagen and an amount of tissue thromboplastin equal to or less than the first reaction part is applied, or Tissue thromboplastin is not applied. The reaction portions may be fabricated/coated with a mixed solution of collagen and tissue thromboplastin with various weight ratio. [0058] In terms of the collagen coating, the coating can be simply carried out with high adhesive strength by, for example, a method in which collagen is dissolved in an acidic solution, and the resulting solution is applied to a predetermined position of the substrate . The microchip has waste liquid reservoirs on the downstream side of the first and second reaction parts, respectively (Fig. 1B; and 1C). [0013] FIG. 1(B) is a plan view of the substrate 1a+1b in which the first inlet 104 (hole) and the second inlet 114 (hole) of the microchip and the first air hole 105 on the first waste liquid reservoir and the second air hole 115 on the second waste liquid reservoir are drilled. The positions of the through holes 104 and 114 are located corresponding to the end of the inlet side of the first channel 101 and the end of the inlet side of the second flow channel 111. The positions of the through holes 105 and 115 correspond to the upper part of the groove corresponding to the waste liquid retention portion 103,113. Hosokawa’s device includes a “two-part” adjoined substrate (1a+1b) as opposed to claimed (and implied) a single piece substrate ( use of one - piece construction instead of the use of separate modules may involves only routine skill in the art ) . Hosokawa’s grooves on the first part substrate (Figt.1A 101; 111) are first ly coated with collagen and /or tissue thromboplastin ([0087]), and then the second part substrate with holes are placed one top of the first part substrate for assembly. Hosokawa does not teach : a separate film on its surface collagen and/or tissue thromboplastin is/are applied, wherein the substrate and the film are attached to each other in such a manner that the surface of the substrate on which the groove is formed and the surface of the film on which collagen and/or tissue thromboplastin is/are applied overlap each other ; OR providing a film on its surface collagen and/or tissue thromboplastin is/are applied in such a manner that an area on the flow path is covered therewith when the film is attached to the substrate; and attaching the film on the substrate in such a manner that the surface of the substrate on which the groove is formed and the surface of the film on which collagen and/or tissue thromboplastin is/are applied overlap each other . Hosokawa does not render obvious the currently presented invention. The internal search report including the written opinion was reviewed; and the references cited in the report were also considered. The examiner also uncovered other prior art references and are cited in PTOL-892. The invention as currently claimed is not anticipated or rendered obvious over the prior art of record. Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled “Comments on Statement of Reasons for Allowance.” Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to FILLIN "Examiner name" \* MERGEFORMAT SHOGO SASAKI whose telephone number is FILLIN "Phone number" \* MERGEFORMAT (571)270-7071 . The examiner can normally be reached FILLIN "Work Schedule?" \* MERGEFORMAT Monday-Thursday 10:00-6:00 . Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, FILLIN "SPE Name?" \* MERGEFORMAT Maris Kessel can be reached at FILLIN "SPE Phone?" \* MERGEFORMAT 5712707698 . The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. FILLIN "Examiner Stamp" \* MERGEFORMAT SHOGO . SASAKI Primary Examiner Art Unit 1798 /SHOGO SASAKI/ Primary Examiner, Art Unit 1758 11/29/2025